MIDAS VERDICT:

Chronic asthma and acute bronchitis are life-altering conditions and cases are growing as people live longer and move to cities where pollution is high. Belluscura can help to make sufferers’ lives easier. Demand for its kit is increasing and the pace should pick up materially next year and beyond. At 56p, the shares are a buy.